Abstract Number: 0270 • ACR Convergence 2021
Impact of Macrophage Cholesterol Loading Capacity and Interactions with Treatments on Cardiovascular Risk and Coronary Atherosclerosis Burden in Rheumatoid Arthritis
Background/Purpose: Statins and bDMARDs may decrease cardiovascular risk in RA by lowering coronary plaque formation, promoting regression and altering the composition of atherosclerotic lesions. Macrophage…Abstract Number: 0407 • ACR Convergence 2021
The Clinical Role of T1 Mapping Cardiac Magnetic Resonance Imaging for Detecting Cardiac Involvement in the Early Stage of Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and internal organs tissue fibrosis including the myocardium. Cardiovascular magnetic resonance (CMR) parametric mapping is a promising…Abstract Number: 0958 • ACR Convergence 2021
Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Background/Purpose: To identify independent risk factors for major adverse cardiovascular (CV) events (MACE) in ORAL Surveillance (NCT02092467), a long-term, randomized, open-label, non-inferiority, Phase 3b/4 safety…Abstract Number: 1653 • ACR Convergence 2021
Positron Emission Tomography-Detected Uptake of 18F-Fluorodeoxyglucose in Visceral and Subcutaneous Adipose Tissue Is Associated with Articular Disease Activity and Arterial Inflammation in Rheumatoid Arthritis
Background/Purpose: Subcutaneous adipose tissue (SAT) from people with RA contains more macrophages and expresses higher levels of cytokines, chemokines, and other inflammatory mediators compared with…Abstract Number: 0271 • ACR Convergence 2021
Higher Prevalence of Subclinical Atherosclerosis in the First Five Years of Rheumatoid Arthritis Diagnosis
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of developing a cardiovascular (CV) event than the general population, due to an accelerated process…Abstract Number: 0446 • ACR Convergence 2021
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
Background/Purpose: This study is an ongoing USFDA post-marketing requirement (2020-2024) to assess the impact of boxed warning on romosozumab (romo) treatment and the feasibility of…Abstract Number: 1007 • ACR Convergence 2021
Vascular Deposition of Oxidized LDL Is Increased in Children with Untreated Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic vasculopathy associated with metabolic derangements and possible increased risk for premature atherosclerosis. Oxidation of low-density lipoprotein (LDL) in…Abstract Number: 1701 • ACR Convergence 2021
Evaluation of Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis Patients, Treated with Biological Agents: 6-month Follow-up
Background/Purpose: Despite new therapeutic approaches in RA, the mortality gap between RA patients and the general population persists, and may even be increasing. Cardiovascular (CV)…Abstract Number: 0273 • ACR Convergence 2021
Abnormalities in Left Ventricular Geometry Influenced by Higher Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Titers in Rheumatoid Arthritis Patients
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing left ventricular (LV) geometry abnormalities which can result in cardiac death. High titers of…Abstract Number: 0572 • ACR Convergence 2021
Circulating Cytokines and Chemokines Are Associated with the Risk of Incident Cardiovascular Disease in Rheumatoid Arthritis Independent of Conventional Disease Activity Measures
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in rheumatoid arthritis (RA). While chronic inflammation contributes to CVD pathogenesis, the role of specific…Abstract Number: 1032 • ACR Convergence 2021
Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Data indicate that minority populations are at higher…Abstract Number: 1748 • ACR Convergence 2021
The Peroxisome Proliferator-Activated Receptor-γ (PPAR) Agonist Pioglitazone Improves Vascular and Metabolic Dysfunction in Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: Premature cardiovascular events in SLE are associated with significant mortality and morbidity with no effective treatments described to date. Both immune dysregulation characteristics of…Abstract Number: 0275 • ACR Convergence 2021
Impact of Disease Activity on Left Ventricular Diastolic Dysfunction in Rheumatoid Arthritis Patients
Background/Purpose: Cardiovascular disease (CVD) is the main cause of mortality in patients with rheumatoid arthritis (RA) reflected by a higher prevalence of cardiovascular risk factors…Abstract Number: 0641 • ACR Convergence 2021
Title: EHR-Supported Staff Protocol Improves Smoking Cessation in a Diverse Rheumatology Clinic: Updated Results of Quit Connect Dissemination
Background/Purpose: Smoking is a risk factor for rheumatologic conditions like lupus and rheumatoid arthritis and predicts worse outcomes. Smoking and rheumatic disease increase risk for…Abstract Number: 1054 • ACR Convergence 2021
Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study
Background/Purpose: Patients with rheumatic diseases (RMD) face an increased cardiovascular (CV) mortality compared to the general population. Still, risk stratification based on traditional cardiovascular risk…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 31
- Next Page »